On October 8, 2026, China’s NIDC released draft guidelines for public comment through October 25, establishing a standardized framework to classify and evaluate new cosmetic ingredients based on composition, intended use, and safety risks. Cosmetics companies should review pipeline ingredients early to align R&D and ensure regulatory compliance.
CIRS Group has systematically compiled and in-depth analyzed the August 2026 new cosmetic ingredient filing information published by the National Medical Products Administration (NMPA).
On August 19, China's IECIC undergoes fifth dynamic adjustment. This article provides a detailed review of these five adjustments.
In July 2026, 18 new cosmetic ingredients were filed with China's NMPA, marking a 64% year-on-year increase and bringing the year-to-date total to 134. Domestic Chinese entities filed 15 of these ingredients—led by Shanghai, Zhejiang, and Guangdong—while overseas companies in Malaysia and the United States filed the remaining three.
This article summarizes the core points based on the Technical General Principles for the Data of Registration and Filing of NCI.
CIRS Group has systematically compiled and in-depth analyzed the June 2026 new cosmetic ingredient filing information published by NMPA.
As of late June 2026, a cumulative total of 109 new cosmetic ingredients have completed filing in China, with six newly added in the past weeks as the pace of filing continues to accelerate.
The MEE Order No. 12 revision may bring new chemical substances in finished cosmetics under environmental registration.
As of mid-June 2026, 10 new cosmetic ingredients have completed filing (notification) in June, bringing the cumulative total for the year to over 100.
CIRS Group has conducted a systematic review and in-depth analysis of the cosmetic ingredient filings published by China's National Medical Products Administration (NMPA) in May 2026.
